Ginkgo Bioworks Holdings, Inc.

NYSE DNA

Ginkgo Bioworks Holdings, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024

Ginkgo Bioworks Holdings, Inc. EPS (Diluted) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Ginkgo Bioworks Holdings, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -17.88, a -680.79% change year over year.
  • Ginkgo Bioworks Holdings, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -2.29, a -1,038.74% change year over year.
  • Ginkgo Bioworks Holdings, Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -0.20.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
SV Wall Street
NYSE: DNA

Ginkgo Bioworks Holdings, Inc.

CEO Dr. Jason Kelly Ph.D.
IPO Date April 19, 2021
Location United States
Headquarters 27 Drydock Avenue
Employees 1,218
Sector Health Care
Industries
Biotechnology
Description

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Similar companies

ENVB

Enveric Biosciences, Inc.

NA

NA

StockViz Staff

February 7, 2025

Any question? Send us an email